Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaAlexander M.M. Eggermont, Caroline Robert, Shahneen Sandhu et al.|New England Journal of Medicine|2018Cited by 1.9k
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or PlaceboAlexander M.M. Eggermont, Stefan Suciu, Michal Kiciński et al.|JAMA Oncology|2020Cited by 439
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 TrialAlexander M.M. Eggermont, Caroline Robert, Christian U. Blank et al.|Journal of Clinical Oncology|2020Cited by 284
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III MelanomaAlexander M.M. Eggermont, Caroline Robert, Michal Kiciński et al.|NEJM Evidence|2022Cited by 152
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver Kennedy, Mario Mandalà, Michal Kiciński et al.|European Journal of Cancer|2022Cited by 51